Market Closed - Euronext Paris 12:35:00 2024-03-28 pm EDT 5-day change 1st Jan Change
0.769 EUR +2.26% Intraday chart for Sensorion -3.88% +78.84%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Sensorion: study results in hearing loss CF
Sensorion Meets Primary Endpoint for Sens-401 Phase 2A Clinical Study for Residual Hearing Preservation CI
Sensorion SA Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Sensorion: completion of private placement CF
Sensorion Announces the Completion of Patient Inclusion in Phase 2A Clinical Trial of Sens-401 for Residual Hearing Preservation After Cochlear Implantation CI
Sensorion Appoints Federico Mingozzi as Non-Executive Director to the Board of Directors CI
Sensorion Extends Maturity of Pre-funded Warrants Issued to Redmile Group MT
Sensorion Receives Go-ahead in France for Phase 1/2 Clinical Trial of Hearing Impairment Treatment MT
Sensorion: clinical trial approved CF
Sensorion Announces Approval to Initiate Lead Gene Therapy Candidate Sens-501 into a Phase 1/2 Clinical Trial in Some European Countries CI
Sensorion: partnership extended with Institut Pasteur CF
Sensorion Extends Partnership Framework Deal with Institut Pasteur MT
Sensorion Announces Partnership with the Institut Pasteur to Accelerate Gene Therapy Programs Targeting Hearing Disorders CI
Sensorion: favorable safety profile in phase 2a trial CF
Sensorion SA Appoints Bernd Schmidt as New Chief Technical Officer CI
Sensorion appoints Director of Technical Operations CF
Sensorion SA Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Sensorion SA announced that it has received ?33.214286 million in funding from Sofimac Innovation SAS, The Invus Group, LLC, Redmile Group, LLC CI
HC Wainwright Initiates Sensorion with Buy Rating MT
Sensorion to Raise EUR35 Million via Private Placement MT
Sensorion SA announced that it expects to receive ?33.214286 million in funding from Sofimac Innovation SAS, The Invus Group, LLC, Redmile Group, LLC CI
Sensorion Submits Clinical Trial Application for OTOF-GT, its Lead Gene Therapy Candidate, in Europe CI
Sensorion Seeks Regulatory Approval for Early-stage Study of Hearing Loss Drug in UK MT
Sensorion Sa Submits Clinical Trial Application for Lead Gene Therapy Candidate Otof-Gt in the Uk CI
Sensorion Reports Positive Efficacy Data from SENS-401 Phase 2a Clinical Study CI
Chart Sensorion
More charts
Sensorion is a clinical-stage biotech company, that specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, a significant global unmet medical need. Sensorion has built a R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and modalities for drug candidates. Its clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) progressing in a proof of concept (PoC) clinical study in cisplatin-induced ototoxicity (CIO) and, with partner Cochlear Ltd, in a study in patients scheduled for cochlear implantation. Sensorion has entered into a strategic collaboration with Institut Pasteur. It has two gene therapy programs, at preclinical stage, aimed at correcting hereditary forms of deafness including deafness caused by a mutation of the gene encoding for Otoferlin, and hearing loss related to mutation in GJB2 gene.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.769 EUR
Average target price
2.167 EUR
Spread / Average Target
+181.75%
Consensus
  1. Stock
  2. Equities
  3. Stock Sensorion - Euronext Paris
  4. News Sensorion
  5. Sensorion Wins Regulatory Nod to Launch Mid-Stage Study of Cisplatin-Induced Hearing Loss Drug